Resmed ventilator safety issue has drawn attention after the U.S. Food and Drug Administration disclosed five serious injuries linked to a malfunction in certain Astral models.
Problem identified in Astral 100 and 150 units
The FDA said a subset of Astral 100 and Astral 150 devices can unintentionally shift into a fail‑safe mode that stops therapy delivery. The fault stems from supercapacitors that may leak over time, damaging the printed circuit board assembly. When the circuit is compromised, the ventilator may halt treatment while in use, or fail to start therapy after being on standby.
According to the agency, patients who cannot sustain spontaneous breathing and lack adequate monitoring face heightened risk if the device stops providing support. The notification, issued on Nov. 10, 2020, referenced an early alert that the company had already sent to customers on June 25.
Company response and supply challenges
Resmed informed its clients that the issue affects roughly 0.1 % of its installed base, based on a review of global post‑market and service records. The firm’s letter noted five adverse events, one classified as serious, and confirmed that all individuals recovered after medical intervention.
To address the defect, Resmed plans a “prioritized and phased approach” that begins with inspections and risk‑mitigation steps for patients deemed most vulnerable. However, the company disclosed that a shortage of replacement circuit boards limits its ability to repair every affected unit promptly.
Because the shortage may also curb the availability of new Astral ventilators, Resmed advised health‑care providers to consider alternative equipment for incoming patients. Facilities still operating units beyond the typical eight‑year service life were urged to evaluate other options for their users.
Related: Intuitive Links Q2 Softness to ACA Subsidy End
Patients depend on reliable ventilation.
The constrained supply of parts could extend repair timelines, potentially leaving some hospitals with devices that remain at risk. While the manufacturer is focusing on the most critical cases first, the broader impact on the market may persist until inventory levels improve.
Regulatory and clinical implications
The FDA’s early alert highlighted the need for vigilant monitoring of patients on the affected machines. It warned that without prompt detection of the fail‑safe state, therapy interruption could lead to severe outcomes. The agency’s statement emphasized that the risk is especially pronounced for individuals lacking alternative ventilation methods.
Resmed’s analysis suggests that the leak‑induced failures are relatively rare, yet the consequences of a single event can be significant. The company’s recommendation to prioritize alternative ventilators for new admissions reflects a precautionary stance amid ongoing component scarcity.
Industry observers may note that the situation highlights the importance of supply‑chain resilience for critical medical devices. Even a small percentage of faulty units can translate into notable patient safety concerns when the equipment is essential for life‑supporting care.